J. W. Coons Advisors LLC Sells 5,000 Shares of Hologic, Inc. (NASDAQ:HOLX)

J. W. Coons Advisors LLC cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 43.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,500 shares of the medical equipment provider’s stock after selling 5,000 shares during the period. J. W. Coons Advisors LLC’s holdings in Hologic were worth $469,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. General Partner Inc. bought a new position in shares of Hologic in the fourth quarter worth about $26,000. Groupama Asset Managment grew its holdings in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC grew its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. boosted its holdings in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. Finally, Covestor Ltd boosted its holdings in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares during the period. 94.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on HOLX. Jefferies Financial Group began coverage on shares of Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target for the company. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Royal Bank of Canada cut their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Evercore ISI cut their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Ten equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $85.77.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.88% of the company’s stock.

Hologic Stock Performance

NASDAQ HOLX opened at $64.47 on Monday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm’s fifty day moving average price is $69.91 and its two-hundred day moving average price is $76.53. Hologic, Inc. has a 1 year low of $62.69 and a 1 year high of $84.67. The firm has a market capitalization of $14.47 billion, a P/E ratio of 20.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.